Neutrophil-lymphocyte Ratio and Platelet-lymphocyte Ratio as Predictors for Adverse Events in EVAR

Inflammation in EVAR Clinical Trial

Official title:

Neutrophil-lymphocyte Ratio and Platelet-lymphocyte Ratio as Predictors for Adverse Events in Endovascular Aneurysm Repair for Abdominal Aorticaneurysm

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04254211
• Other study ID #: NLR, PLR in EVAR
• Status: Completed
• Start date: March 1, 2016
• Est. completion date: November 1, 2019

Study information

• Verified date: April 2021
• Source: University of Thessaly
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study investigated the association of chronic inflammatory markers with the clinical outcome after endovascular aneurysm repair (EVAR) for abdominal aortic aneurysm.

Description:

The study included 230 consecutive AAA patients, treated electively by EVAR from March 2016 to February 2019. The values of simple inflammatory markers,neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), were measured pre- and postoperatively.Adverse events included any major adverse cardiovascular events (MACE), acute kidney injury and death from any cause.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 230
• Est. completion date: November 1, 2019
• Est. primary completion date: February 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• AAA

• Elective

• EVAR

Exclusion Criteria:

• Emergency

• Open surgery

Related Conditions & MeSH terms

• Inflammation
• Inflammation in EVAR

Intervention

Other:
• NLR
neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR)

Locations

Country	Name	City	State
Greece	Univeristy of Thessaly	Larissa	Thessaly

Sponsors (1)

Lead Sponsor	Collaborator
University of Thessaly

Country where clinical trial is conducted

Greece, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	NLR major cardiovascular events (MACE)	NLR indicator for major cardiovascular events (MACE)	Day 4 postopertively
Primary	PLR major cardiovascular events (MACE)	PLR indicator for major cardiovascular events (MACE)	Day 4 postopertively
Primary	NLR acute kidney injury (AKI)	NLR indicator for acute kidney injury (AKI)	Day 4 postopertively
Primary	PLR acute kidney injury (AKI)	PLR indicator for acute kidney injury (AKI)	Day 4 postopertively
Primary	NLR death	NLR indicator for death	Day 4 postopertively
Primary	PLR death	PLR indicator for death	Day 4 postopertively